Home › Nexvet And Zenoaq Announce PD-1 mAb Candidate For Canine Cancer
 

Keywords :   


Nexvet And Zenoaq Announce PD-1 mAb Candidate For Canine Cancer

2016-05-03 02:58:08| drugdiscoveryonline Home Page

Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, and Zenoaq (Nippon Zenyaku Kogyo Co., Ltd.), a leading Japanese animal health company, announced today their research and development collaboration has yielded fully caninized, or ‘100% dog’, monoclonal antibodies (mAbs) that bind and potently inhibit the immuno-oncology target programmed cell death protein 1 (PD-1).

Tags: cancer candidate announce canine

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
02.11Subtropical Storm Patty Update Statement
02.11Summary for Subtropical Storm Patty (AT2/AL172024)
02.11Atlantic Tropical Weather Outlook
02.11Eastern North Pacific Tropical Weather Outlook
02.11Weekly Recap: Nippon Paint, AkzoNobel, PPG Top This Weeks Stories
02.11Subtropical Storm Patty Graphics
02.11Subtropical Storm Patty Forecast Discussion Number 1
02.11Subtropical Storm Patty Wind Speed Probabilities Number 1
More »